Worldwide Heparin Shortage

Maanas Deodhar 1, Surabhi Fadnavis 1, Atul Laddu 1, Jawed Fareed 2
1 - Global Thrombosis Forum, Suwanee, GA and 2 - Loyola University, Chicago, IL.

Background

Heparin, a widely used **anticoagulant**, plays a pivotal role in preventing blood clots. or treatment of DVT and PE. Heparin is derived from animal tissues, specifically from pig intestines. However, a **global shortage** of heparin has been reported in ecent years, primarily due to disruptions in the supply chain, particularly in China, the world's largest producer of heparin. This shortage has raised alarms across the medical community and posed challenges in patient management.

Objectives

- **Investigate the causes** of the global heparin shortage
- **Propose actionable solutions** to mitigate the crisis, including alternative sources, synthetic options, and clinical management strategies.

Methods

A **comprehensive review** of literature, data from regulatory agencies, and industry reports was conducted to explore:
- The primary **causes** behind the heparin shortage, with a focus on supply chain disruptions.
- Potential **alternatives** to animal-derived heparin.
- Clinical strategies for **prioritizing heparin use i**n hospitals during times of shortage.

Results

Key Causes of the Heparin Shortage

1. China's Dominance in Heparin Production:
- 80% of global heparin is sourced from China, primarily from pig's intestinal mucosa.
- African Swine Fever (ASF), which affected China's pig population, resulted in a significant reduction in the production of heparin, directly contributing to the shortage.
- ASF wiped out over one-third of Chinas pig population, severely threatening global heparin supply, which typically amounts to over 30 trillion international units annually.

Results (Contd.)

2. Environmental Factors and Global Trade:
- Trade disruptions causedsignificant delays in heparin shipments.
- Regulatory delays in approving alternative sources also amplified the shortage.

3. FDA and Regulatory Solutions
The FDA has been actively involved in mitigating the heparinshortage through the following strategies:
- Approval of alternative sources of heparin, such as bovine-derived heparin from South America (Brazil and Argentina).
- Encouraging the use of alternative anticoagulants, such as:
  * Danaparoid, ancrod, r-hirudin, abciximab, tirofiban, and argatroban (for patients with heparin intolerance).
  *Low Molecular Weight Heparins (LMWH) like Lovenox (Enoxaparin) and fondaparinux (Arixtra), which can serve as substitutes. Research and Industry Solutions

4. Synthetic Alternatives:
- Development of synthetic anticoagulants that do not rely on animal-derived heparin is a promising long-term solution.
- Enzymatic approaches to synthesizing heparin-like compounds without the need for animal tissues have been under investigation.
- Advances in biotechnology may lead to the production of heparin substitutes from recombinant DNA technology or plant-based sources.
- Researchers are also focused on optimizing polydispersity and enhancing the bioavailability of synthetic compounds.

Clinical Strategies to Manage the Shortage

1. Prioritization of Heparin Use:
- Heparin should be prioritized for high-risk patients, such as those undergoing cardiac surgeries, dialysis, and acute thromboembolic events.
- Emergent use of UFH should be reserved for acute conditions.
- Elective surgeries or procedures may use alternatives or delay anticoagulation therapy.
2. Hospitals and Action Plans:
- Hospital systems should implement action plans to reduce heparin usage while ensuring that critical cases are prioritized.
- Example: At Massachusetts General Hospital, a VTE prophylaxis pathway led to an 84% reduction in heparin use without compromising patient safety.

3. Expanding Global Supply Chains:
- Global manufacturers must expand their supplier base to include regions unaffected by ASF, such as Europe and South America.
- Countries may also consider stockpiling heparin to prevent future shortages in case of geopolitical or environmental disruptions

Conclusion

Heparin remains an indispensable anticoagulant in modern medicine. The global shortage, can be mitigated with the combined efforts of the FDA, clinicians, pharmacists, and industry leaders. The following steps can **address the crisis:**

- Prioritize **high-risk patients** for heparin use.
- Expand alternatives, including **synthetic and bovine-derived** options.
- **Collaborate globally t**o ensure consistent supply chains and reduce dependency on single-source production.

References

1. Fareed, J., et al. (2021). "Global Heparin Shortage: Impact and Solutions." Journal of Thrombosis and Haemostasis, 19(5), 1243-1251.
2. Gomes, WJ Leal, JC Braile, DM et al.: A Brazilian perspective for the use of bovine heparin in open heart surgery, Int J Cardiol, 223:611-612, 2016
3. Kishimoto, TK Viswanathan, K Ganguly, T et al.: Contaminated heparin associated with adverse clinical events and activation of the contact system, N Engl J Med. 2008; 358:2457-2467
4. McCarthy, Cian P; Vaduganathan, Muthiah; Edmond Solomon, Edmond, et al: Running thin: implications of a heparin shortage, The Lancet, 395, 534 - 536, 2020.
5. Vilanova, E, Tovar, AMF, and Mourao, PAS: Imminent risk of a global shortage of heparin caused by the African swine fever afflicting the Chinese pig herd, J Thromb Haemost., 17:254-256, 2019